firmagon
ferring pharmaceuticals a/s - degareliks - nowotwory stercza - terapia endokrynologiczna - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
symago 25 mg tabletki powlekane
symphar sp. z o.o. - agomelatinum - tabletki powlekane - 25 mg
imago pro 350 sc
agrovena sp. z o.o._x000d_ ul. hallera, 86-100 Świecie - chlorek mepikwatu - 300 g, _x000d_ proheksadion wapnia - 50 g - regulator wzrostu
bimago 240 od
crop agro sp z.o.o ul. koralowa, 86-031 osielsko - tiachlopryd - 240 g - insektycyd
degarelix accord
accord healthcare s.l.u. - degarelix acetate - nowotwory stercza - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
orocal d3 forte 1000 mg + 800 iu tabletki do rozgryzania i żucia
takeda pharma sp. z o.o. - calcii carbonas; cholekalcyferol - tabletki do rozgryzania i żucia - 1000 mg + 800 iu